Where does the idea of cycling come from?
Cycling is a habit borrowed from bodybuilding culture, where fixed “on” and “off” calendars are passed from user to user. The thinking is usually that a break keeps the body from getting used to a compound or gives the system time to reset. Those calendars are rarely based on trials of the specific peptide, and they treat every peptide the same way.
In practice, the peptides men ask about fall into two groups that are managed differently. Recovery peptides are about an injury that should heal. Growth hormone peptides are about a hormone level that should stay in range. The right schedule follows from that difference.
| Recovery peptides | Growth hormone peptides | |
|---|---|---|
| Examples | BPC-157, TB-500, Wolverine stack | Sermorelin, tesamorelin |
| Purpose | Support recovery from a specific injury | Raise growth hormone and IGF-1 for a body composition or recovery goal |
| How long | A defined course, then reassess | Ongoing, reviewed at set intervals |
| What decides the next step | Whether the injury has improved | IGF-1, blood sugar and results |
| Status, October 2026 | Unsettled; no final FDA rule | Tesamorelin FDA-approved (Egrifta); sermorelin compounded |
Why are recovery peptides run in defined courses?
Because the goal has an end point and the safety data are thin. A recovery peptide is used to support healing of a particular tendon, ligament or muscle problem. Once it has healed, or clearly has not responded, there is no reason to keep going.
The evidence also argues for the shortest course that does the job. A 2025 systematic review of BPC-157 found 36 studies, all but one in animals or cells, and no clinical safety data in humans. For TB-500, the FDA’s notes on bulk substances say it identified no human exposure data. With so little known about long-term use, open-ended courses make little sense.
These peptides also have an unsettled regulatory status. BPC-157 and TB-500 left the FDA’s safety-concern list in April 2026, and an advisory committee voted to recommend them for compounding in July, but there is no final rule. Our Wolverine stack page explains what that means for the combination.
How are growth hormone peptides reassessed instead?
With labs at set intervals rather than a calendar. Sermorelin and tesamorelin raise your own growth hormone, and the liver answers with IGF-1. MedlinePlus notes that IGF-1 is the steadier measure because growth hormone itself rises and falls through the day.
The tesamorelin label shows why the check matters. In its trials, 47 percent of patients had IGF-1 more than 2 standard deviation scores above the mean after 26 weeks, and 36 percent were above 3, with elevations appearing as early as 13 weeks. The label advises monitoring IGF-1, considering stopping if it stays very high, and weighing whether to continue in people whose abdominal fat has not come down. It also asks for glucose checks before and during treatment.
So the decision at each check-in is one of four things: continue, lower the dose, pause, or stop. Our page on IGF-1 on sermorelin or tesamorelin shows how those results are read.
What happens when you stop a growth hormone peptide?
The benefit can fade, which is the strongest argument against stopping on a whim. In the tesamorelin label’s extension phase, people switched from tesamorelin to placebo at week 26 saw their visceral fat rise again by week 52, by about 22 percent in one study and 16 percent in the other.
That does not mean you are locked in forever. It means a planned stop, with a strategy to protect results through training, nutrition and weight, works better than an arbitrary break. Our answer on how long peptides take to work covers the timeline in the other direction.
Do peptides stop working if you never take a break?
There is little human research on tolerance to these specific peptides, so no one can give you a reliable break schedule to prevent it. The practical way to find out whether yours is still working is the same check used to start it: IGF-1, how your body composition is changing, and how you feel. If those flatten despite good adherence, your provider can adjust or stop the peptide based on that evidence.
How Ultimate Male schedules reassessment
In our peptide therapy program, every plan starts with blood work, including IGF-1, metabolic and hormone markers, and a one-on-one consultation. Follow-up labs and a check-in come at six to eight weeks, then adjustments as you respond, with draws done on site in San Gabriel or Downey.
For recovery peptides, your provider will tell you where FDA status stands before any course is discussed. For growth hormone peptides such as tesamorelin, the length of treatment is decided by your labs and results at each visit. Ask about schedules and costs on the free 10-minute call.
